

**Collagen Type II Cleavage ELISA  
ITEM #60-1001-001****(C2C ELISA)****1. OVERVIEW****1.1 PRINCIPLE OF PROCEDURE**

This assay measures a neopeptide created by the cleavage of type II collagen by collagenases. This neopeptide is at the C-terminus of the  $\frac{3}{4}$  piece of type II collagen cleavage product. In arthritis, this neopeptide is increased in the serum.

This assay is for *in vitro* research use only and has been optimized for analyzing human serum, but has also been used to analyze various types of samples and species. It has been designed to be used for comparative analysis only, and is not to be used for absolute diagnostic purposes. All samples must be treated the same way and in the recommended manner.

**1.2 PRINCIPLE OF THE ASSAY**

This assay is a competitive immunoassay in a 96-well plate format using a mouse monoclonal antibody and a synthetic peptide to represent the neopeptide (Poole *et al*, 2004). This synthetic peptide is conjugated to a protein and pre-coated onto the C2C ELISA plate. C2C peptide standards or unknown serum samples are added to a polypropylene mixing plate, followed by a specific mouse IgG antibody (C2C antibody formerly called the col 2  $\frac{3}{4}$  long antibody). This mixture is pre-incubated to allow the antibody to bind to the free C2C peptide. The pre-incubated samples are then transferred from the polypropylene mixing plate onto the C2C ELISA plate and incubated to allow the antibody to bind either to the C2C coating conjugate on the plate, to the C2C standards or to the endogenous neopeptide in serum samples. After washing the C2C ELISA plate, goat anti-mouse horseradish peroxidase (GAM-HRP) conjugate is added, which binds to any mouse antibody on the C2C ELISA plate. After washing the C2C ELISA plate again, Tetramethylbenzidine (TMB) is added and then GAM-HRP degrades H<sub>2</sub>O<sub>2</sub> and oxidizes TMB to form a blue product. The reaction is stopped and the signal amplified with an acid, which converts the product from a blue to a yellow colour that can be quantified at 450 nm. The optical density (OD) at 450 nm is inversely proportional to the amount of neopeptide present in the sample.

**1.3 BACKGROUND**

Joint cartilage is composed of a type II collagen-based fibrillar network complexed to proteoglycans. Type II collagen consists of 3 identical  $\alpha$  chains arranged in a triple helix that form fibrils. Within this fibrillar meshwork resides the large aggregating proteoglycan aggrecan. In arthritis, type II collagen is extensively cleaved and destroyed by the activity of collagenases, which results in loss of type II collagen (Billinghurst *et al*, 1997). Different collagenases, namely MMP-1, MMP-8 and MMP-13, can cleave type II collagen. The neopeptide that is created at the C terminus of the primary cleavage site is recognized by the C2C antibody which is specific for type II collagen.

The assay can be used to analyse degradation in articular cartilages revealing increased cleavage of type II collagen by collagenases (Dejica *et al*, 2008). Serum C2C is increased in rheumatoid arthritis (RA) and baseline levels are prognostic of progression (Verstappen *et al*, 2006). Singly or in combination with the C1,2C and CPII assays together with clinical information, Early serum biomarker responses to therapy at 1 month are predictive of radiologic changes at 12 months (Mullan *et al*, 2007).

In knee osteoarthritis (OA), serum C2C in combination with the CPII assay can be used to help discriminate progressors from non-progressors (Cahue *et al*, 2007). Strong correlations between serum C2C and MRI T2 images have been reported (King *et al*, 2004).

---

IBEX Pharmaceuticals Inc.

In animal models of arthritis, serum C2C is elevated in a rat polyarthritis model and decreases with effective therapy (Song *et al*, 1999). Serum C2C in conjunction with CPII assay is reflective of natural OA progression in the guinea pig as in patients (Huebner and Kraus, 2006).

Although most studies to date have examined serum, recent findings (Cibere *et al*, 2009) indicate the importance of also analyzing urine. Different results may be obtained which may prove more informative, such as regarding OA onset and progression in OA. Analyses of urine have revealed that the C2C antibody recognizes a 45-mer peptide (Nemirovskiy *et al*, 2007; Ibex, unpublished). Urine C2C but not serum C2C is elevated in patients with pre-radiographic knee OA (Cibere *et al*, 2009). The differences would appear related to the concentration of the disease-related 45-mer peptide in urine. C2C levels are elevated in synovial fluid in a rabbit RA model (Kojima *et al*, 2001). In a dog model of OA, C2C is elevated in synovial fluid, serum and urine following surgery (Matyas *et al*, 2004; Chu *et al*, 2002).

## 2. PROTOCOL

***Bring C2C ELISA kit to room temperature (20-25°C) before use. Wear gloves for all steps of the protocol.***

**Note 1: Gently centrifuge small tubes before opening to ensure proper recovery of reagents.**

**Note 2: Reagents and samples must be gently vortexed just before use.**

- Make standards according to Table 1.
- Add 50 µL of C2C Standards and samples to appropriate wells of the polypropylene mixing plate. Serum samples should be diluted 1/2 with Buffer III. This can be done directly on the plate (25 µL serum + 25 µL Buffer III).
- Add 50 µL of C2C Antibody diluted in Assay Buffer to all wells of the polypropylene mixing plate (One Plate: 50 µL of Ab + 6 mL Assay Buffer).
- Pre-incubate the polypropylene mixing plate on a high speed Titre Plate Shaker at 600-700 rpm for 30 minutes (± 2 minutes) at room temperature (20-25°C).
- Remove the C2C ELISA plate from the foil bag. Transfer 80 µL of antigen-antibody mixture from each well of the polypropylene mixing plate to the corresponding wells of the ELISA plate using a multi-channel pipette.
- Incubate the ELISA plate on a high speed Titre Plate Shaker at 600-700 rpm for 1 hour (± 5 minutes) at room temperature (20-25°C).
- Wash the ELISA Plate 3 times. Blot the plate dry on towels after the last wash.
- Add 100 µL/well of GAM-HRP conjugate diluted in Buffer III. (One Plate: 22 µL of GAM-HRP Conjugate + 11 mL Buffer III).
- Incubate the ELISA plate on a high speed Titre Plate Shaker at 600-700 rpm for 30 minutes (± 2 minutes) at room temperature (20-25°C).
- Wash the ELISA Plate 6 times. Blot the plate dry on towels after the last wash.
- Add 100 µL/well of TMB.
- Incubate the ELISA plate on a high speed Titre Plate Shaker at 600-700 rpm for approximately 30 minutes at room temperature (20-25°C). Monitor colour development at 630 nm if necessary.
- Stop reaction with 100 µL of Stop Solution/well.
- Read plate at 450 nm within 10 minutes.

### 3. EQUIPMENT & MATERIALS

#### Required Equipment not Supplied

- ELISA plate reader that can perform dual wavelengths (OD at 450 nm and reference at 630 nm) would be preferred.
- Precision pipettes to dispense 20-1000 µL
- 8 channel adjustable pipette
- Vortexer
- Titre Plate Shaker capable of 600-700 revolutions per minute (rpm)
- Automatic ELISA plate washer.

**Supplied Materials** (Store all reagents at 2-8°C unless indicated otherwise until the expiration date on the label).

- C2C Standard Stock. 10 µg/mL. Make up 7 levels of Standards from this stock in Buffer III. (Stds. 0, 10, 50, 100, 200, 500 and 1000 ng/mL)
- C2C ELISA plate. ELISA plate coated with C2C peptide conjugate within a stabilizing matrix including BSA. Packaged dry in a foil pouch with desiccant sachet.
- Polypropylene mixing plate.
- Assay Buffer. Protein based buffer containing BSA, normal goat serum and a non-mercury preservative. For dilution of primary antibody.
- Buffer III. Protein based buffer containing BSA and a non-mercury preservative. For dilution of Standards and secondary antibody.
- C2C antibody. Primary mouse antibody in a protein based buffer containing BSA and a non-mercury preservative.
- GAM-HRP Conjugate. Secondary antibody in a protein based buffer containing BSA and a non-mercury preservative.
- Wash buffer (25X). Contains buffered saline with a non-ionic detergent. Prepare wash buffer as needed by dilution in deionized water. e.g. For 1000 ml of wash buffer solution take 40 ml of the concentrated Wash buffer (25X) and complete to 1000 ml with deionized water. **Wash buffer contains no preservative. Store at 4°C after dilution for no more than one week.**
- TMB. A solution of tetramethylbenzidine (TMB) in a proprietary buffer.
- Stop Solution. Contains 0.2 M sulfuric acid.

**CHEMICAL HAZARD**

Avoid contact with reagents containing sulfuric acid. In case of contact with any of these reagents, wash thoroughly with water.

#### 4. PROCEDURAL NOTES

- The following recommendations must be followed in order to achieve the most reliable results :
  - Collect your samples, freeze them at -70°C and, if applicable, run all timepoints at the same time (refer to section 5 for details).
  - Analyze all timepoints from the same individual on one plate and group your samples as much as possible.
  - Use the same kit lot number for the entire study.
  - The results from the timepoints of one individual should be compared in proportion to each other in order to evaluate the trends over time.
  - The best results will be obtained by analyzing test samples in triplicate.
  - If a sample must be re-tested, perform the re-test with associated timepoints, i.e. if one timepoint is unexpected, retest this timepoint along with at least one or two additional timepoints from the same individual.
- We recommend centrifuging small tubes to maximize recovery of reagent. Reagents are overfilled to ensure required volume can be recovered.
- All reagents and samples must be gently vortexed just before use.
- Stock reagents should be diluted shortly before use. Final dilutions of antibody and HRP conjugate are not stable for more than one day. Final dilutions of standards are stable for up to 1 week at 2-8°C.
- A set of Standards (in duplicate) must be included on each plate.
- Buffer III is provided to make up Standards for the measurement of serum and plasma samples. Ideally, a matrix equivalent to the sample should be used to make up standards. For example; for tissue culture, supernatant medium may be used.
- Samples should ideally be analyzed as triplicates. All samples to be compared must be subject to the same treatment.
- Avoid microbial contamination of reagents, especially the stock antibodies and conjugates.
- GAM-HRP is highly sensitive to microbial contamination, sodium azide, hypochlorous acid and aromatic hydrocarbons often found in laboratory water supplies.
- TMB is highly sensitive to light and should not be exposed to silica based materials such as glass or metal.

#### 5. SPECIMEN COLLECTION & STORAGE

Blood should be collected without anticoagulants and in such a way as to avoid haemolysis. Ideally, serum samples should be aliquoted, immediately frozen and stored at -70 °C following centrifugation (600g/3000rpm, 10 min) to remove particulate material and any clots. Aliquots of serum can be stored at -70°C for more than a year. Repeated freeze thaw cycles should be avoided.


## 6. RESULTS

- Plot mean standard absorbance readings on the y-axis versus log concentration on the x-axis using a logistic equation (4 or 5 parameter). Note that the standard curve is sigmoidal and not linear. Ideally, appropriate curve fitting software should be used.
- Any sample reading higher than the highest standard should be diluted with Buffer III and re-assayed. Any sample reading lower than the lowest standard should be re-assayed or discarded.

Table 1

C2C Working Standards Dilution Table				
Std #	Concentration	Volume Stock	Vol. Buffer III	Dilution
1)	1 µg/mL Stock	50 µL of 10 µg/mL Stock	450 µL	1:10
2)	500 ng/mL	25 µL of 10 µg/mL Stock	475 µL	1:20
3)	200 ng/mL	100µL of 1 µg/mL Stock	400 µL	1:5
4)	100 ng/mL	50µL of 1 µg/mL Stock	450 µL	1:10
5)	50 ng/mL	50 µL of 500 ng/mL	450 µL	1:10
6)	10 ng/mL	50 µL of 100 ng/mL	450 µL	1:10
7)	0 ng/mL	-	500 µL	

Representative C2C Standard Curve



IBEX Pharmaceuticals Inc.

## 7. SPECIFIC PERFORMANCE CHARACTERISTICS

### 7.1 CROSS REACTIVITY AND SPECIFICITY

The C2C antibody has selective high affinity for collagenase-cleaved human type II collagen. It recognizes the  $\alpha$ -chain fragments containing an approximate 9 amino acid sequence from the carboxy terminus of the three-quarter length piece produced by collagenase (MMP-1, MMP-8 and MMP-13) cleavage of type II collagen. This antibody demonstrates no cross reactivity with uncleaved human type I or II collagen  $\alpha$ -chains or uncleaved triple-helical and heat denatured human types I and II collagen. It also shows no reactivity to similarly cleaved type I collagen  $\alpha$ -chains.

This antibody has broad cross reactivity and recognizes human, as well as monkey, horse, bovine, dog, rabbit, rat, mouse and guinea pig C2C. The antibody has not been tested in other species. We strongly recommend testing the performance of the kit in your conditions.

This assay is suitable for serum. It has also been used by Ibx customers in plasma, synovial fluid, urine and culture medium.

This ELISA utilizes a mouse antibody. Testing of samples containing high concentrations of mouse antibodies (such as mouse serum) can result in high background interference.

***End-users should conduct their own validation for these and any other samples.***

## 8. REFERENCES

- Billinghurst, R.C., Dahlberg, L., Ionescu M., Reiner A., C Bourne R., Rorabeck C., Mitchell P., Hambor J, Diekmann O., Tschesche H., Chen J., Van Wart H. and Poole A.R. (1997). Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. *J. Clin. Invest.* 99:1535-1545.
- Cahue S., Sharma L., Dunlop D., Ionescu M., Song J., Lobanok T., King L., and Poole A.R. (2007). The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. *Osteoarthritis and cartilage* 15: 819-23.
- Chu Q., Lopez. M., Hayashi K., Ionescu M., Billinghurst R.C., Johnson K.A., Poole A.R. and Markel M.D. (2002). Elevation of a collagenase generated type II collagen neopeptide and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. *Osteoarthritis and Cartilage* 10: 662-669.
- Cibere J., Zhang H., Garnero P., Poole A.R., Lobanok T., King L., Saxne T., Kraus V.B., Way A., Thorne A., Wong H., Singer J., Kopec J., Guermazi A., Peterfy C., Nicolaou C., Munk P. and Esdaile J.M. (2009). Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. *Arthritis and Rheumatism* 60: 1372-1380.
- Dejica V.M., Mort J.S., Laverty S., Percival M.D., Antoniou J., Zukor D.J. and Poole A.R. (2008). Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. *Am. J. Pathol.* 173:161-9.
- Huebner J.I. and Kraus V.B. (2006). Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. *Osteoarthritis and Cartilage* 14: 923-30.
- King K.B., Lindsey C.T., Dunn T.C., Ries M.D., Steinbach L.S. and Majumdar S. (2004). A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. *Magnetic resonance imaging* 22: 1117-23.
- Kojima, T., Mwale F., Yasuda T., Girard C., Poole A.R. and Laverty S. (2001). Early degradation of type IX and type II collagens with onset of experimental inflammatory arthritis. *Arthritis Rheum.* 44:120-127.

---

IBEX Pharmaceuticals Inc.

- Matyas J.R., Atley L., Ionescu M., Eyre D.R. and Poole A.R. (2004). Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. *Arthritis and Rheumatism* 50: 543-52.
- Mullan R.H., Matthews C., Bresnihan B., FitzGerald O., King L., Poole A.R., Fearon U. and Veale D.J. (2007). Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. *Arthritis and Rheumatism* 56: 2919-28.
- Nemirovskiy O.V., Dufield D.R., Sunyer T., Aggarwal P., Welsch D.J. and Mathews W.R. (2007). Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. *Analytical Biochem.* 361: 93-101.
- Poole A.R., Ionescu M., Fitzcharles M.A. and Billingham R.C. (2004). The assessment of cartilage degradation *in vivo*: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. *J.Immunological methods* 294: 145-53.
- Song, X-Y, Zeng L., Jin W., Thompson J., Mizel D.E., Lei K-J., Billingham R.C., Poole A.R. and Wahl S.M. (1999). Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. *J Exp. Med*, 190: 535-542.
- Verstappen S.M.M., Poole A.R., Ionescu M., King L.E., Abrahamowicz M., Hofman D.M., Bijlsma J.W.J., Lafeber F.P, J.G. and the Utrecht Rheumatoid Arthritis Cohort Study Group (2006). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers:an evaluation from 1 to 4 years after diagnosis. *Arthritis Research and Therapy*: R31.